



Republic of the Philippines  
Department of Health  
**OFFICE OF THE SECRETARY**

September 1, 2020

**DEPARTMENT CIRCULAR**

No. 2020- 0326


**TO :** ALL UNDERSECRETARIES; ASSISTANT SECRETARIES; DIRECTORS OF BUREAUS, CENTERS FOR HEALTH DEVELOPMENT AND SERVICES; EXECUTIVE DIRECTORS OF SPECIALTY HOSPITALS, AND NATIONAL NUTRITION COUNCIL; CHIEFS OF MEDICAL CENTERS, HOSPITALS, SANITARIA AND INSTITUTES; PRESIDENT OF THE PHILIPPINE HEALTH INSURANCE CORPORATION; DIRECTORS OF PHILIPPINE NATIONAL AIDS COUNCIL AND TREATMENT AND REHABILITATION CENTERS; AND OTHERS CONCERNED

**SUBJECT :** DIRECTIVE FOR THE CONDUCT OF ALL CLINICAL TRIALS FOR COVID-19

In order to centralize information and communication on the conduct of clinical trials, the Department of Health (DOH) mandates all principal investigators of all clinical trials for COVID-19 drugs and vaccines to notify DOH and submit relevant information using the attached Clinical Trial Notification Form and weekly updates to the Health Research Division ([covid19evid@gmail.com](mailto:covid19evid@gmail.com); subject: [Clinical Trial]) of the Health Policy Development and Planning Bureau, and to the Health Regulation Team ([hrt.clinicaltrial@gmail.com](mailto:hrt.clinicaltrial@gmail.com)). Select trial information will be made publicly available through the COVID-19 Local Evidence Database (<https://hpdpb.doh.gov.ph/health-research-division/doh-covid-19-evidence-database/>).

The Department of Health also reiterates Administrative Order No. 2020-0010 entitled "Regulation on the Conduct of Clinical Trials for Investigational Products," which states the requirements needed for the conduct of clinical trials.

Dissemination of the information to all concerned is requested.

  
**FRANCISCO T. DUQUE III, MD, MSc**  
Secretary of Health

**RESCINDED** by

No. 2022-0132  
Date FEB 22, 2022  
Posted on/by: MAR 8, 2022 /my

## CLINICAL TRIAL NOTIFICATION FORM

<b>Clinical Trial Information</b>					
<b>Full Title of Clinical Trial</b>					
<b>Principal Investigator /Institution/Email and Mobile Number</b>					
<b>Trial Sponsor/s</b>					
<b>Phase to be conducted</b>	Phase I	Phase II	Phase III	Phase IV	Others (specify) _____
<b>Attachments</b>	<ul style="list-style-type: none"> <li>Approval Letter from the FDA</li> <li>Approval Letter from PHREB-accredited Level 3 REC and Institutional Endorsement Letter</li> <li>Clinical Trial Protocol and Protocol Amendment/s</li> </ul>				
<b>Name of Investigational Product</b>					
<b>Proposed indication and Dosage information</b>					
<b>Target population/ Characteristics of trial subjects</b>					
<b>Total number of subjects in the Philippines</b>					
<b>Expected start date:</b>					
<b>Expected end date</b>					
<b>STUDY SITES (Provide tabulation on a separate sheet if necessary)</b>					
<b>Name of Study Site</b>	<b>Site Investigator</b>		<b>Contact Details (Email and Contact Number)</b>		